In this pivotal episode of The Bone Health Basement Tapes, host Peter Bianco is joined by Dr. Mary Bouxsein—Professor of Orthopedic Surgery at Harvard Medical School and a central leader behind the SABRE initiative—alongside Dr. Shannon Carpenter, founder of The Bone Health Clinic.

At the center of the conversation is SABRE (Study to Advance Bone Mineral Density as a Regulatory Endpoint), a landmark effort that has reshaped the future of osteoporosis drug development. Drawing on data from over 50 clinical trials and more than 160,000 patients, SABRE demonstrated that changes in bone mineral density (BMD) can reliably predict fracture risk reduction—paving the way for smaller, faster, and more efficient clinical trials.

But this episode goes far beyond regulatory science.

Together, the group explores why this moment may represent a true “Big Bang” for bone health—a long-awaited inflection point where innovation, investment, and infrastructure may finally converge. With shorter and less costly trials, the barriers that have stalled new drug development for years may begin to fall, unlocking a new wave of therapies in a field that has seen limited progress since 2019.

From the clinical front lines, Dr. Carpenter brings a powerful perspective on the everyday reality of fragility fractures—still vastly underdiagnosed and undertreated despite the availability of effective therapies. The discussion highlights a critical gap: up to 90% of patients remain untreated even after a fracture, underscoring that the challenge is not just innovation, but implementation.

The episode also dives into the broader system implications:

• How shifting trial design may move the bottleneck from measurement to patient identification
• The emerging role of opportunistic imaging and AI in early detection
• The growing strain on DXA capacity and the need for alternative screening pathways
• The lack of infrastructure and trained providers to manage newly identified patients
• The importance of earlier intervention—well before age 65

Perhaps most importantly, the conversation reframes osteoporosis itself—from an inevitable part of aging to a preventable and treatable condition. As Dr. Bouxsein emphasizes, bone health is foundational to longevity: without mobility, healthspan collapses.

The episode closes with a forward-looking vision: a future where bone health is assessed earlier, treated proactively, and fully integrated into mainstream healthcare—supported by aligned incentives, better education, and increased public awareness.

If SABRE reaches its full potential, this may be the moment the field finally shifts—from reacting to fractures to preventing them.

Bone health is often addressed only after a fracture occurs, leaving a large gap between scientific knowledge and everyday clinical practice. In this episode of The Bone Health Basement Tapes, we sit down with Dr. Shannon Carpenter, an orthopedic surgeon who took an unconventional path—building a clinical practice dedicated specifically to bone health.

Dr. Carpenter founded The Bone Health Clinic to focus on early identification of skeletal risk, comprehensive evaluation, and long-term management of bone health. Rather than treating fractures alone, her model is designed to identify patients at risk before those fractures happen.

The conversation explores what led an orthopedic surgeon to move upstream into prevention, the operational realities of building a dedicated bone health practice, and the broader implications for how bone health care may evolve in the coming years. As diagnostic technologies improve and fracture risk becomes more visible earlier in the patient journey, practice models like this may represent an early signal of a larger shift in how skeletal health is delivered.

This episode examines what happens when bone health becomes the central focus of a clinical practice—and what that might mean for the future of fracture prevention.

In this episode of The Bone Health Basement Tapes, we sit down with Dr. Sundeep Khosla — endocrinologist, researcher, and one of the central scientific figures in modern bone health. Dr. Khosla has spent his career at the Mayo Clinic asking foundational questions about why the skeleton ages and fails, and his answers helped change how the field thinks about bone loss in both women and men. His research on sex steroids and skeletal aging revealed that estrogen is not just a female story — it plays a quiet but decisive role in male bone health as well, a finding that reshaped clinical thinking and opened new lines of research.

In this conversation, we trace the arc of that scientific journey: how skeletal biology evolved from descriptive observation into molecular and cellular precision, what the field got wrong along the way, and how decades of careful research eventually produced drugs capable of reducing fracture risk by as much as 70%. We also examine the troubling gap between what science achieved and what medicine delivered — including Dr. Khosla's 2016 paper documenting a dramatic collapse in osteoporosis treatment rates at exactly the moment the tools to prevent fractures had never been better.

It is a conversation about discovery, about the institutions and mentors that make science possible, and about what happens when a field wins the scientific battle but struggles to translate it into care.